Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions
Dimitrios Stefanoudakis,
Evaggelia Karopoulou,
Alkis Matsas,
Georgia Anna Katsampoula,
Ermioni Tsarna,
Eleni Stamoula,
Panagiotis Christopoulos
Affiliations
Dimitrios Stefanoudakis
Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, 76 Vasilissis Sofias Avenue, 11528 Athens, Greece
Evaggelia Karopoulou
Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, 76 Vasilissis Sofias Avenue, 11528 Athens, Greece
Alkis Matsas
Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, 76 Vasilissis Sofias Avenue, 11528 Athens, Greece
Georgia Anna Katsampoula
First Department of Propaedeutic Surgery, Hippocration Hospital, Athens Medical School, National and Kapodistrian University, 11528 Athens, Greece
Ermioni Tsarna
Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, 76 Vasilissis Sofias Avenue, 11528 Athens, Greece
Eleni Stamoula
Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
Panagiotis Christopoulos
Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, 76 Vasilissis Sofias Avenue, 11528 Athens, Greece
Gynecological cancers pose a significant burden on women’s health worldwide, necessitating innovative treatment approaches. Immunotherapy has emerged as a promising strategy, harnessing the body’s immune system to combat cancer. This review aims to provide a comprehensive overview of the current landscape and future directions of immunotherapy in cervical and endometrial cancer. Methods: A thorough literature search was conducted to identify relevant studies and clinical trials. The main methods and treatments employed in immunotherapy for cervical and endometrial cancer, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies, are briefly described. Results: Immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, have shown remarkable clinical efficacy in certain gynecological malignancies, particularly in advanced or recurrent cases. Additionally, ongoing research on cancer vaccines and adoptive cell therapies holds promise for personalized and targeted treatment options.
